Table 5.
Distribution of Response to Chemotherapy with Cyclosporin A Based on Time from Development of Resistance for Patients with Gynecologic Malignancies.
| Patient no. | Time (months)a | Chemotherapy | Response | Cancer type |
| 15 | 0 | Cisplatin | Progression | Cervix |
| 20 | 0 | Cisplatin | Progression | Cervix |
| 21 | 0 | Cisplatin | Progression | Cervix |
| 25 | 0 | Etoposide/Cisplatin | CR | Choriocarcinoma |
| 1 | 0 | Cisplatin | CR | Uterus |
| 13 | 0 | Taxol | CR | Uterus |
| 28 | 0 | Cisplatin | CR | Uterus |
| 9 | 0 | Cisplatin | Stable | Uterus |
| 23 | 0 | Carboplatin | Progression | Uterus |
| 12 | 5 | Carboplatin | Progression | Uterus |
| 18 | 0 | Cisplatin | Not evaluable | UteruS |
a
Interval between chemotherapy agent + cyclosporin A and the previous use of the same agent. Time 0 represents addition of cyclosporin A after progression while on the same chemotherapy drug. (CR, complete response; PR, partial response).